Starpharma company secretary retires this week
10 December, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) CFO Nigel Baade will take on the responsibilities of company secretary Ben Rogers who is retiring, effective from Friday.
Ascend, 3M team for cancer vaccine research
09 December, 2013 by Dylan Bushell-EmblingAscend Biopharmaceuticals has entered an agreement with 3M Drug Delivery Systems to evaluate conjugating a 3M agonist with Ascend's ASN cancer vaccine platform.
Biotron's BIT225 can clear out HIV reservoir pools
06 December, 2013 by Dylan Bushell-EmblingNew data from a Biotron (ASX:BIT) study of its BIT225 drug candidate suggest it can reduce the quantity of virus in HIV reservoir cells as well as stopping HIV replication.
GTG's breast cancer risk test is cost-effective
06 December, 2013 by Dylan Bushell-EmblingA virtual trial of Genetic Technologies' (ASX:GTG) BREVAGen genetic test for breast cancer risk shows it is most cost-effective in women with an intermediate risk.
Big congresses down under
03 December, 2013Australia appears to have reached tipping point and is starting to attract large international congresses bringing thousands of delegates to our shores.
Minomic seeks to set prostate cancer test standard
02 December, 2013 by Dylan Bushell-EmblingSydney biotech Minomic aims to commercialise a new prostate cancer test in Australia in 2015-16 and hopes it will become the new diagnostic standard within five years.
Alchemia cleared to continue HA-Irinotecan trial
02 December, 2013 by Dylan Bushell-EmblingThe DSMB monitoring Alchemia's (ASX:ACL) phase III trial of HA-Irinotecan in metastatic colorectal cancer has, for the fourth time, recommended that the trial continue.
New treatment for osteoporosis
28 November, 2013A compound that stimulates bone formation in animal models holds promise as a new type of medicine for osteoporosis.
Clarity, Viralytics get new board members
28 November, 2013 by Dylan Bushell-EmblingClarity Pharmaceuticals has selected a new executive chairman, while fellow Sydney biotech Viralytics (ASX:VLA) has appointed a melanoma expert to its scientific advisory board.
Innate Immunotherapeutics launches $12m IPO
27 November, 2013 by Dylan Bushell-EmblingAfter moving to Australia last month, New Zealand-born Innate Immunotherapeutics has kicked off an IPO, aiming to raise up to $12m for phase IIb trials of its SPMS drug candidate.
Novogen files for US anticancer patents
27 November, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has applied for a family of US patents covering its newly licensed anti-tropomyosin cancer drug technology.
Novogen spikes on JV's ovarian cancer discovery
25 November, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) shares grew more than 18% after the company announced its new JV has discovered that lead drug candidate Trilexium can destroy ovarian cancer spheroids.
Biotron gets ethics nod for HCV trial
21 November, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has received ethics approval for a three-month trial of the new capsule formulation of antiviral drug BIT225 in hepatitis C patients.
Supporting Indigenous health and wellbeing
20 November, 2013A philanthropic donation of $10 million for Indigenous health has been gifted to the University of Western Australia.
Patrys wins new Aussie patent for cancer antibody
19 November, 2013 by Dylan Bushell-EmblingPatrys has been granted a second Australian patent - its seventh globally - covering anticancer antibody PAT-SM6.
